Stock Research for BIOVF


Featured Broker: Ally Invest

Get the due diligence for another stock.


BIOVF Stock Chart & Research Data

The BIOVF chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the BIOVF chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


BIOVF Due diligence Resources & Stock Charts

The BIOVF stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View BIOVF Detailed Price Forecast - CNN Money CNN View BIOVF Detailed Summary - Google Finance
Yahoo View BIOVF Detailed Summary - Yahoo! Finance Zacks View BIOVF Stock Research & Analysis -

Stock Analysis

TradeIdeas View BIOVF Trends & Analysis - Trade-Ideas Barrons View BIOVF Major Holders - Barrons
NASDAQ View BIOVF Call Transcripts - NASDAQ Seeking View BIOVF Breaking News & Analysis - Seeking Alpha
Spotlight View BIOVF Annual Report - OTC Report View BIOVF OTC Short Report -
TradeKing View BIOVF Fundamentals - TradeKing Charts View BIOVF SEC Filings - Bar Chart
WSJ View Historical Prices for BIOVF - The WSJ Morningstar View Performance/Total Return for BIOVF - Morningstar
MarketWatch View the Analyst Estimates for BIOVF - MarketWatch CNBC View the Earnings History for BIOVF - CNBC
StockMarketWatch View the BIOVF Earnings - StockMarketWatch MacroAxis View BIOVF Buy or Sell Recommendations - MacroAxis
Bullish View the BIOVF Bullish Patterns - American Bulls Short Pains View BIOVF Short Pain Metrics -

Social Media Mentions

StockTwits View BIOVF Stock Mentions - StockTwits PennyStocks View BIOVF Stock Mentions - PennyStockTweets
Twitter View BIOVF Stock Mentions - Twitter Invest Hub View BIOVF Investment Forum News - Investor Hub
Yahoo View BIOVF Stock Mentions - Yahoo! Message Board Seeking Alpha View BIOVF Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for BIOVF - Insider Cow View Insider Transactions for BIOVF - Insider Cow
CNBC View BIOVF Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for BIOVF - OTC Markets
Yahoo View Insider Transactions for BIOVF - Yahoo! Finance NASDAQ View Institutional Holdings for BIOVF - NASDAQ

Stock Charts

FinViz View BIOVF Stock Insight & Charts - StockCharts View BIOVF Investment Charts -
BarChart View BIOVF Stock Overview & Charts - BarChart Trading View View BIOVF User Generated Charts - Trading View

Latest Financial News for BIOVF

Sobi and Novimmune Selected as Honourees for 2019 National Organization for Rare Disorders (NORD) Rare Impact Award in Industry Innovation for Gamifant® (emapalumab)
Posted on Monday March 25, 2019

STOCKHOLM, March 25, 2019 /PRNewswire/ -- Sobi™ and Novimmune SA have both been selected as honourees by the National Organization for Rare Disorders (NORD) for the 2019 Rare Impact Awards. The companies were nominated in the category of Industry Innovation in recognition of the US Food and Drug Administration (FDA) approval in November 2018 of Gamifant® (emapalumab-lzsg) for the treatment of paediatric (newborn and older) and adult patients with primary haemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance to conventional HLH therapy. The Rare Impact Awards recognise individuals, organisations and industry innovators for outstanding work in support of the rare disease community.

Invitation to Sobi Capital Markets Day 14 May 2019
Posted on Thursday February 21, 2019

The event will take place at Karolinska Institutet Biomedicum, Solnavägen 9, Solna, from 12:30 – 16:30. The Capital Markets Day will be an opportunity for institutional investors, analysts and media to learn more about Sobi, our therapeutic areas and future growth strategy as well our financial performance. The agenda and more detailed information about the event will be published on Sobi's website closer to the event.

Sobi Presents Comprehensive Study Data on Extended Half-life Haemophilia Treatments at EAHAD
Posted on Thursday February 07, 2019

STOCKHOLM, Feb. 7, 2019 /PRNewswire/ -- Sobi™ will present data at the European Association of Haemophilia and Allied Disorders (EAHAD) conference in Prague, Czech Republic, 6-8 February 2019, showing evidence on the safety, efficacy and long-term benefits of its extended half-life products for the treatment of haemophilia. The studies that will be presented support Sobi's commitment to develop a treatment paradigm that expand the possibilities and transform life for people with haemophilia. Sobi and our collaboration partner Sanofi will provide interim data on the incidence of inhibitors in previously untreated patients (PUPs) with severe haemophilia A treated with factor VIII Fc fusion protein (Elocta®): the PUPs A-LONG study.

Sobi™ to Acquire Synagis® US Rights From AstraZeneca - Creates a Platform for Global Growth
Posted on Monday November 12, 2018

STOCKHOLM, Nov. 13, 2018 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (SOBI.ST) has entered into agreements to acquire the perpetual rights to Synagis® (palivizumab) in the US from AstraZeneca and to participate in 50 per cent of the future earnings of the candidate drug MEDI8897 in the US. The total upfront consideration corresponds to USD 1,500 M (SEK 13.6 B[1]), consisting of USD 1,000 M (SEK 9.1 B) in cash and USD 500 M (SEK 4.5 B) equivalent in newly issued Sobi shares.

Stock Market & Investing Books

Enter a stock symbol to view the stock details.